Results 1 to 10 of about 26,259 (260)

Cardiovascular adverse events associated with bispecific antibodies in relapsed or refractory B-cell non-Hodgkin lymphomas. [PDF]

J Hematol Oncol
Munir M, Sayed A, Lee DH, Awan F, Ghazi S, Kim J, Addison D, Epperla N.   +7 more
europepmc   +1 more source

Breakthroughs of bispecific antibodies therapy in multiple myeloma: latest updates from 2025 ASH. [PDF]

Biomark Res
Zhao B, Bu Q, Chen AL, Zhu HH.
europepmc   +1 more source

Bispecific Antibodies in Breast Cancer Immunotherapy: Mechanisms, Advances, and Translational Challenges. [PDF]

Target Oncol
Brogna MR, Ferrara G, Varone V, Montone A, Fava A, Schiano MR, DelSesto M, Pizza N, Prota A, Barra C, Collina F.   +10 more
europepmc   +1 more source

Bispecific antibody toxicities

Canadian Medical Association Journal
Britto, Joanne, Mian, Hira, Davies, Gwynivere A., Balitsky, Amaris K.   +3 more
openaire   +2 more sources

Editorial: Bispecific antibodies and their conjugates in solid tumors and hematological malignancies. [PDF]

Front Immunol
Püsküllüoğlu M, Pacholczak-Madej R.
europepmc   +1 more source

Advances in the clinical application of bispecific antibodies in cancer therapy. [PDF]

iScience
Zhou S, Li F, Niu M, Wu K, Li T, Yi M.
europepmc   +1 more source

Efficacy and safety of approved cellular therapies and bispecific antibodies in solid tumors: the current state. [PDF]

Discov Oncol
Jafry RZ, Qamar SB, Irfan S, Abid MA, Mohlere V, Maithel N, Jafri SH, Awasthi S, Srour S, Vaziri IA, Abid MB.   +10 more
europepmc   +1 more source

Tocilizumab prophylaxis for patients with multiple myeloma treated with bispecific antibodies. [PDF]

Blood Adv
Kowalski A, Lykon J, Diamond B, Coffey D, Kaddoura M, Maura F, Hoffman J, Pandey A, Kazandjian D, Landgren O.   +9 more
europepmc   +1 more source

Real-world incidence of severe infections in multiple myeloma patients receiving bispecific antibodies: a meta-analysis. [PDF]

Ann Hematol
Spataro F, Desantis V, Einsele H, Dammacco F, Vacca A, Ria R, Solimando AG.   +6 more
europepmc   +1 more source

BCMA-targeted bispecific antibodies in relapsed/refractory multiple myeloma: three approvals, many questions. [PDF]

Oncologist
Al Hadidi S, Khan AM, Afrough A, Anderson LD.   +3 more
europepmc   +1 more source